Loading...
Loading...
CDTX| Name | Value |
|---|---|
| Revenues | 10.2M |
| Cost of Revenue | 0.0M |
| Gross Profit | 10.2M |
| Operating Expense | 23.5M |
| Operating I/L | -13.3M |
| Other Income/Expense | 0.2M |
| Interest Income | 0.0M |
| Pretax | -13.1M |
| Income Tax Expense | 0.3M |
| Net Income/Loss | -13.4M |
Cidara Therapeutics, Inc. is a biotechnology company specializing in the development and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology. Its lead product candidate, rezafungin acetate, is a novel echinocandin antifungal designed for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis. The company also leverages its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza, RSV, HIV, and SARS-CoV-2 strains causing COVID-19.
